Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
Abstract Background Selective RET inhibitors have been approved by the Chinese government for the treatment of RET-rearranged non-small cell lung cancer. This study aimed to illustrate the efficacy and safety of selective RET inhibitors in a real-world clinical context in China. Methods Patients wit...
Saved in:
| Main Authors: | Siyu Lei, Linyan Tian, Lu Yang, Yaning Yang, Junling Li, Xingsheng Hu, Xuezhi Hao, Haiyan Xu, Yan Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13155-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01) -
Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC)
by: An Wang, et al.
Published: (2024-11-01) -
First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma
by: Tatsuru Eihuku, et al.
Published: (2024-01-01) -
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)